The Impact of TFPI2 and TERT Gene Alterations on Brain Cancer Patient Survival and Cancer Cell Viability
Seo Jin Lee
BranksomeHall Asia, Seogwipo, South Korea
Publication date: September 23, 2024
BranksomeHall Asia, Seogwipo, South Korea
Publication date: September 23, 2024
ABSTRACT
Tissue factor pathway inhibitor 2 (TFPI2) and telomerase reverse transcriptase (TERT) affect the immortality of brain cancer stem cells. Previous studies showed that the silence of TFPI2 and TERT genes decreases the stemness of tumor cells. Therefore, we investigated the effect of TFPI2 and TERT gene underexpression on A172 and SHSY5Y cells. A172 is a human glioblastoma cell line, and SH-SY5Y is a human neuroblastoma cell line. They are often used in cancer research to study the aggressive and invasive nature of glioblastoma and neuroblastoma. The experiment result showed significant morphological changes in A172 cells with TFPI2 underexpression to fibroblast-like cell shape. After incubating for seven days, we found that cell viability decreased significantly in siRNA-TERT and siRNA-TFPI2+TERT samples. Also, A172 cells with TFPI2 underexpression formed specific aggregations. Furthermore, the combined underexpression of TFPI2 and TERT had a synergistic effect, resulting in a more pronounced decrease in cell viability compared to the individual gene silencing treatments. These results suggest that TFPI2 and TERT underexpression synergistically disrupt the cancerous characteristics of A172 cells, with TFPI2 specifically contributing to morphological alterations.
Tissue factor pathway inhibitor 2 (TFPI2) and telomerase reverse transcriptase (TERT) affect the immortality of brain cancer stem cells. Previous studies showed that the silence of TFPI2 and TERT genes decreases the stemness of tumor cells. Therefore, we investigated the effect of TFPI2 and TERT gene underexpression on A172 and SHSY5Y cells. A172 is a human glioblastoma cell line, and SH-SY5Y is a human neuroblastoma cell line. They are often used in cancer research to study the aggressive and invasive nature of glioblastoma and neuroblastoma. The experiment result showed significant morphological changes in A172 cells with TFPI2 underexpression to fibroblast-like cell shape. After incubating for seven days, we found that cell viability decreased significantly in siRNA-TERT and siRNA-TFPI2+TERT samples. Also, A172 cells with TFPI2 underexpression formed specific aggregations. Furthermore, the combined underexpression of TFPI2 and TERT had a synergistic effect, resulting in a more pronounced decrease in cell viability compared to the individual gene silencing treatments. These results suggest that TFPI2 and TERT underexpression synergistically disrupt the cancerous characteristics of A172 cells, with TFPI2 specifically contributing to morphological alterations.
